How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Novel medical indication of Baclofen and other GABAB receptor specific agonists from University of Frankfurt Hospital

Organization name

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH


Baclofen applies as a prototype of GABAB receptor specific agonists. For over 30 years it has been used to treat spastic disorders because of its muscle-relaxing and analgetic properties. Later, GABAB receptor specific agonists of 2nd and 3rd generation have been developed including allosteric modulators of GABAB receptor such as CGP 7930 or GS 39783.

So far, known uses of (ant)agonists of GABAB receptors include the therapy of diseases of the neural system, like multiple sclerosis, but also of the alimentary system, lung, kidney and bile.

New Concept

Scientists from the University Hospital of Frankfurt am Main found that baclofen significantly improves the medical therapy in a so far unknown field of medical application. Furthermore, the results implicate that other GABAB receptor specific agonists hold a comparative potential.

The new indication applies to a multitude of patients mainly in industrialised countries. According to the physicians this means an important enhancement of today´s possibilities of treatment for these patients.

Application Advantages 

  • Improvement of conventional methods to treat diseases of the new indication field. 
  • Clinical studies and pharmacological data regarding side effects of treatment with baclofen or other GABAB receptor specific agonists are already available.  

Project Status

Experiments in cell culture and using models in mice proceeded successfully. First studies in patients showed very good results. A patent for Germany is applied for. 

Licensing or assignment of the technology is possible as well as a cooperation for further development of the invention. 

Additional data and contact information are provided in the attached pdf.


To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries